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KESAN KEMO-PEMEKAAN KURKUMIN TERHADAP DOS RENDAH 
SISPLATIN PADA SEL-SEL TUNJANG KANSER PARU-PARU SEL 
BUKAN KECIL 
 
 
ABSTRAK 
 
Kanser sel tunjang mewakili populasi kecil ketumbuhan dan memiliki ciri-ciri 
sel tunjang akan tetapi mempunyai daya rintangan terhadap ejen sitotoksik yang 
menjadi penyebab kepada kanser berulang. Bahan semulajadi seperti kurkumin yang 
tinggi kandungan polifenol mempunyai ciri kemo-pemekaan dan kemampuan untuk 
memeka kanser sel tunjang kepada agen sitotosik seperti sisplatin. Oleh itu, kajian ini 
telah dirancang untuk mengkaji keberkesanan kurkumin sebagai kemo-pemekaan 
terhadap kanser sel tunjang paru-paru dan juga menganalisa kadar perencatannya 
terhadap aktiviti kanser sel tunjang menggunakan garis sel A549 dan H2170 yang 
berasal daripada kanser paru-paru sel bukan kecil (NSCLC).  Garis-garis sel NSCLC 
dikultur dan kemudian, dirawat dengan pelbagai kepekatan sisplatin dan kurkumin 
untuk mendapatkan separuh kepekatan merencat (IC50) menggunakan teknik 3-(4, 5-
dimethylthiazol-2-yl)-2H-tetrazolium, inner salt (MTS). Kanser sel tunjang paru-paru 
dengan fenotip CD166+EpCAM+ telah dipencilkan menggunakan fluorescence-
activated cell sorting (FACS). Keberkesanan kurkumin untuk memeka kanser sel 
tunjang diperhatikan melalui ujikaji apoptosis dan ciri-ciri sel tunjang seperti 
kemampuannya untuk bermigrasi, membentuk koloni dan sferoid sel. Ekspresi gen 
yang terlibat dalam apoptosis dan pembaharuan diri dinilai berdasarkan mRNA dengan 
menggunakan tindak balas rantaian polymerase masa nyata. Kesan kurkumin terhadap 
persekitaran kanser sel tunjang dianalisis dengan menggunakan spektrometri jisim 
kromatografi cecair (LCMS). Hasil kajian mendapati pendedahan garis-garis sel 
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NSCLC terhadap kurkumin (10 µM – 40 µM) mengurangkan peratusan sel yang hidup 
kepada purata ~51% dan ~54% terhadap A549 and H2170. Tambahan lagi, pemekaan 
NSCLC terhadap kurkumin menyebabkan pengaruhan apoptosis terhadap 
CD166+EpCAM+ kanser sel tunjang sebanyak 18% dan 20% masing-masing pada 
A549 dan H2170. Di samping itu, kurkumin juga merangsang kemampuan perencatan 
sisplatin terhadap migrasi CD166+EpCAM+ kanser sel tunjang dengan penurunan 
sebanyak 9% dan 21% pada A549 dan H2170. Ini membuktikan kurkumin dapat 
meningkatkan pemekaan kanser sel tunjang terhadap sisplatin sekaligus merencatkan 
migrasi sel. Kurkumin menunjukkan kesan yang signifikasi (p<0.001) dengan 
kemampuan menghalang pembentukan koloni sebanyak 50% - 57% dan kekecutan 
sferoid di dalam A549 CD166+EpCAM+ dan  H2170 CD166+EpCAM+ kanser sel 
tunjang sekaligus membuktikan perencatan terhadap kemampuan pembaharuan sel 
seperti yang ditunjukkan pada pengawalaturan menurun SOX2, NANOG dan KLF5 
yang dikawal atur secara menurun. Ekspresi APAF1, CASPASE-9 dan 
CYTOCHROME-C dikawal atur secara menaik manakala CYCLIN D-1 dikawal atur 
secara menurun mencadangkan gabungan rawatan adalah pro apoptosis dan 
merangsang kitaran sel terhenti lalu menyebabkan perencatan kanser sel tunjang. 
Tambahan lagi, kurkumin mempamerkan keupayaan merencatkan protein kemo-
rintangan seperti aldehyde dehydrogenase (ALDH) lantas menunjukkan potensi terapi 
menggunakan kurkumin untuk mensasar kanser sel tunjang NSCLC. 
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THE CHEMO-SENSITISATION EFFECT OF CURCUMIN AGAINST LOW DOSE 
CISPLATIN ON NON-SMALL CELL LUNG CANCER (NSCLC) STEM CELLS 
 
 
ABSTRACT 
 
Cancer stem cells (CSCs) represent a small subpopulation within a tumour that 
possesses the stem-like properties but are also initiating resistance towards cytotoxic 
agent which contribute to cancer relapse. A natural compound such as curcumin that 
contains high polyphenol has been found to possess chemo-sensitivity effect with an 
ability to sensitise the CSCs to the cytotoxic agents such as cisplatin. Therefore, the 
present study was designed to investigate the efficiency of curcumin as a chemo-
sensitiser in lung CSCs and to analyse its inhibitory effect on CSCs activity using A549 
and H2170 cell lines that belong to non-small cell lung cancer (NSCLC). The NSCLC 
cell lines cultures were treated with various concentrations of cisplatin and curcumin 
to obtain the inhibitory concentration (IC50) using 3-(4, 5-dimethylthiazol-2-yl)-2H-
tetrazolium, inner salt (MTS) assay. The lung CSCs with phenotype CD166+EpCAM+ 
was isolated using fluorescence-activated cell sorting (FACS). The efficiency of 
curcumin to sensitise lung CSCs was observed on apoptosis and stemness 
characteristics including migration ability, colonies and spheroid formation. The 
mRNA level was analysed for genes involved in apoptosis and stemness using 
quantitative real time-polymerase chain reaction (RT-qPCR). Liquid chromatography 
mass spectrometry (LCMS) was used to evaluate the effect of curcumin on CSC niche. 
The results discovered that exposure of NSCLC cell lines to curcumin (10 µM – 40 
µM) reduced the percentage of cells viability to an average of ~51% and ~54% in both 
A549 and H2170. Furthermore, sensitisation of NSCLC to curcumin induced the 
apoptosis of CD166+EpCAM+ CSC subpopulation by 18% and 20% in A549 and 
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H2170 cells respectively. Moreover, curcumin also enhanced the inhibitory capability 
of cisplatin on CD166+EpCAM+ CSC subpopulation, as manifested by the reduction 
of cell migration to 9% and 21% in both A549 and H2170 respectively, representing 
that curcumin may increase the sensitivity of CSC to cisplatin inducing migratory 
inhibition. Curcumin significantly (p<0.001) suppressed the formation the of colonies 
by 50%- 57% and shrank the spheroid in A549 and H2170 CD166+EpCAM+ CSC 
subpopulations thus indicating the inhibition of self-renewal capability as manifested 
by down-regulated of SOX2, NANOG and KLF5. The APAF1, CASPASE 9 and 
CYTOCHROME-C were up-regulated while substantial decreased in CYCLIN D-1 
suggested that the combined treatments were pro apoptosis, induced cell cycle arrest 
thus triggering inhibition of CSCs. Curcumin also has demonstrated its ability to 
inhibit the chemo-resistance protein, aldehyde dehydrogenase (ALDH) therefore 
demonstrated the potential therapeutic approach of using curcumin in targeting CSC 
sub-population in NSCLC.
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CHAPTER 1: INTRODUCTION 
 
PREFACE 
 
Some findings and protocols presented in this thesis have been published in 
Oncology Report journal. The research article published in Oncology Report entitled 
“Curcumin improves the efficacy of cisplatin by targeting cancer stem-like cells 
through p21 and cyclin D1-mediated tumour cell inhibition in non-small cell lung 
cancer cell lines” (Baharuddin et al., 2016) covers all results presented in this thesis. 
Permission to republish the data included in the manuscript has been obtained from 
the respective journals (Appendix A). 
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1.1 Cancer 
Cancer is uncontrollable dividing growth of abnormal cells. It can develop 
anywhere in the body and may eventually spread to other parts of the tissues and 
organs. Cancer begins when genetic changes impaired therefore acquires a series of 
gene mutations that leads to uncontrollable growth thus forming a tumour (Futreal et 
al., 2004). Typically, tumour can be malignant or benign. A malignant tumour is a 
cancerous tumour that is capable of spreading to other parts of the body while benign 
tumour is non-cancerous and will not spread. The common type of cancers are 
carcinomas, sarcomas, leukaemias and lymphomas (www.cancer.net). Carcinomas 
usually are from solid tumours which begin in the skin that cover the surface of internal 
organs such as prostate, breast, lung and colorectal cancer. While sarcomas develop in 
the tissue that connect the body such as blood, muscles, nerves, tendons, joints or bone. 
Whereas, leukaemias is a blood cancer and lymphomas begin in the lymphatic system 
that help to fight the infection. The hallmarks of cancer are based on six characteristics 
(Hanahan & Weinberg, 2011).; 1) able to sustain proliferative signalling; 2) able to 
evade growth suppressors; 3) able to resist cell death; 4) enabling replicative 
immortality; 5) able to induce angiogenesis and 6) capable of activating invasion and 
metastasis. 
 
1.2 Global incidence of cancer 
Cancer is a leading cause of death worldwide accounting for 8.8 million deaths 
in 2015. In the latest cancer statistic reported in 2016, the overall cancer incidence in 
Unites States was estimated 1,685,210 cases or equivalent to 4,600 new cancers was 
diagnosed each day. It was also indicated that cancer is expected to commonly occur 
in men with 42% than women with 38%.  Based on recent cancer statistics (Siegel et 
al., 2016), in men, 44% of all cases covering the prostate, lung, bronchus and colorectal 
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cancer while in women, the 3 most common cancer types are breast, lung and bronchus 
that account for 29% of new cancer diagnosed. The recent trends in cancer incidence 
highlight 4 major types of cancer as having the leading incidence rates with lung cancer 
having the highest incidence rate followed by breast, prostate and colorectal cancer. 
Cancer occurrence also varies among the ethnic groups. It was revealed that black men 
have the highest overall cancer incidence and death rates than the Hispanic white men 
(Siegel et al., 2016). Factor contributing to racial disparities include access to high 
quality of health care such as cancer prevention and early detection facilities. 
According to US Census Bureau in 2014, 26% of black men are burden with poverty 
while 12% live without health insurance. Moreover, black men are unlikely to receive 
standard cancer therapies especially for lung, breast, colorectal and prostate cancer 
(Bach et al., 2002).  
 
1.3 Cancer in Malaysia 
The increase in trends of cancer incidence in Malaysia attracts attention of 
many government and non-government sectors. The establishment of Majlis Kanser 
Kebangsaan (MAKNA) or National Cancer Council, National Cancer Society 
Malaysia, Institut Kanser Negara and numerous research institutes in academic 
institutions, including Institut Pengajian Tinggi Awam (IPTA) and Institut Pengajian 
Tinggi Swasta (IPTS) or non-academic institution such as Institute Medical Research 
(IMR) shows the Malaysian government commitment towards eradicating cancer 
diseases. According to Malaysian National Cancer Registry Report (MNCR), during 
the period between 2007 and 2011, a total of 103,507 new cancer cases were diagnosed 
which included 45.2% reported cases in males and 54.8% reported cases in females. 
The five most common cancers among males were colorectum (16.3%), lung (15.8%), 
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nasopharynx (8.1%), lymphoma (6.8%) and prostate (6.7%) cancers. In the other hand, 
among females, the most common were breast (32.1%), colorectum (10.7%), cervix 
uteri (7.7%), ovary (6.1%) and lung (5.6%) cancers. MNCR also reported the 
incidence of 10 common cancers in Malaysia and the top three were breast, colorectal 
and lung cancers in descending order (Table 1.1). 
 
Table 1.1  Ten most common cancer incidence in Malaysia, 2007-2011.  
Data collected from MNCR. 
Cancer type Number of cases % 
Breast 18,343 17.7 
Colorectal 13,693 132 
Trachea, Bronchus, Lung 10,608 10.2 
Lymphoma 5,374 5.2 
Nasopharynx 5,090 4.9 
Leukaemia 4,573 4.4 
Cervix Uteri 4,352 4.2 
Liver 4,128 4.0 
Ovary 3,472 3.4 
Stomach 3,461 3.3 
Others 30,413 29.4 
Total 103,507 100.0 
 
 
1.4 Lung cancer 
The most common death-causing cancer types as reported by World Health 
Organization in 2015 (www.who.int/cancer) are lung cancer with 1.69 million deaths, 
followed by liver cancer (788, 000 deaths), colorectal cancer (774, 000 deaths), 
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stomach cancer (754, 000 deaths) and breast cancer (571, 000 deaths). A recent cancer 
statistic published in 2016 revealed that lung and bronchus cancer has taken first place 
among others types of cancer in both males and females with 27% and 26%, 
respectively (Siegel et al., 2016). Meanwhile, in Malaysia, according to MNCR, lung 
cancer accounts for 10.2% of all cancers in Malaysia during the period of 2007-2011. 
The distribution of lung cancer in Malaysia has shown changes in pattern, in which 
squamous cell carcinoma (SCC) was the most common cell type in the past whilst 
adenocarcinoma (AC) is the most common cell type in recent years (Liam et al., 2006). 
 
Lung cancer consists of heterogenous groups in pathological features and is 
commonly classified into the following two major types, small cell lung carcinoma 
(SCLC) and non-small cell lung carcinoma (NSCLC). SCLC comprises nearly 20% of 
lung cancer cases (Okudela et al., 2011, Freitas et al., 2014).  In fact, SCLC is fast-
growing and rapidly spreads compared to NSCLC which grows and spreads more 
slowly (Freitas et al., 2014). Approximately 80-85% of lung cancer is classified as 
NSCLC (Mou et al., 2011). NSCLC also is a group of heterogenous histological types, 
the majority of which are AC and SCC with roughly similar frequencies (30-40% 
each), and large cell carcinoma (LCC) with a lower frequency (<10%) (Okudela et al., 
2011, Freitas et al., 2014) 
 
Targeting NSCLC in lung tumours would be necessary as it comprises of 
approximately 85% cases with 5 years survival rates (Chen et al., 2014, Zheng, 2016). 
At least 70% of surgical cases come from AC that occupied almost 60% of the NSCLC 
cases (Lewis et al., 2014). In 2014, there is an intense effort on studying AC 
pathogenesis with the inclusive molecular profiling (Cancer Genome Atlas Research 
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Network, 2014). The study found 18 mutated genes such as Ras like without CAAX 1 
(RITI), epidermal growth factor receptor (EGFR), RNA binding motif protein 10 
(RBM10), neurofibromin 1 (NF1), MET proto-oncogene (MET), er-b2 receptor 
tyrosine kinase 2 (ERBB2) and others, some of which were commonly found in female 
and male patients. Meanwhile, SCC represent 20% of lung cancer cases (Lewis et al., 
2014) and can be categorised into three subtypes; 1. Keratinizing SCC, 2. Non-
keratinizing SCC and 3.basaloid SCC (Travis et al., 2015). Previously, treatment for 
SCC is difficult as no molecular target agents have been established. However, in 
2012, a comprehensive genomic study (Cancer Genome Atlas Research Network, 
2012) of SCC was conducted in Cancer Genome Atlas project. The information 
emanated from this project were used for subsequent beneficial studies that eventually 
led to new therapeutic approach such as using Nivolumab (Brahmer et al., 2015) or 
Pembrolizumab (Garon et al., 2015) for SCC treatments. Apart from that, LCC only 
comprises of 3% lung cancer cases but its diagnostic and clinical properties are yet to 
be properly understood. This is due to lack of evidence of morphologic differentiations 
and immunohistochemical characteristics (Rekhtman et al., 2013) thus its diagnosis 
required more attention under light microscope and validation through 
immonohistochemical staining. 
 
In this study, the A549 and H2170 cell lines derived from NSCLC were used 
to represent the AC and SCC. According to cytogenetic information from ATCC, the 
A549 is a hypotriploid human cell line with the modal chromosome number of 66, 
occurring in 24% of cells. Unlike normal cells that have 46 chromosomes, both A549 
and H2170 having an abnormality karyotype with 68 and 61 chromosome number 
respectively (Zakaria, 2017). The A549 cells are positive for keratin by 
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immunoperoxidase staining (www.atcc.org) and was able to synthesis lecithin with 
high percentage of desaturated fatty acids which essential for the maintenance of 
membrane phospholipids in cells (www.a549.com). The AC often expressing 
mutations in the K-ras oncogene and is characterised by peripheral location in the lung. 
The SCC are centrally located and usually carry p53 gene mutations (Nacht et al., 
2001). In the aspects of etiology, SCC is attributed to tobacco smoking while AC 
remains  unclear (Bennett et al., 1999, Hainaut & Pfeifer, 2001). Briefly, both cells 
were originated from human lung tissue of male donor and showed epithelial 
morphology and are adherent type of cells. Precisely, A549 cell line was established 
in 1972 by D.J. Giard through explant culture of lung carcinomatous tissue from a 58-
year-old Caucasian male while, H2170 was described to be squamous carcinoma 
disease which was established in April 1989 from non-smoker male donor. All the data 
were documented by the America Type Culture Collection (ATCC) 
(http://www.atcc.org). Human lung fibroblast (IMR-90) was a normal human lung cell 
used for the toxicity study. This cell was derived from W.W. Nichols and was 
associated from the lungs of a 16-week female foetus. The cells are epithelial 
morphology like and are adherent type of cells. 
 
1.5 The risk factors associated with lung cancer 
Tobacco smoking is the most factor contributing to many types of respiratory 
diseases including  lung cancer (Hackshaw et al., 1997, Zhong et al., 2000). Sadly, the 
active smokers not only harm themselves, but they also harm the people surrounding 
them by second hand smoke. The second hand smoke is defined as exhalation of smoke 
by a smoker and the burning tip of cigarette (Law & Hackshaw, 1996) subsequently 
causes a contaminant in air , thus it is inhaled by everyone exposing both smokers and 
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non-smokers to its dangerous effect causing the risk to lung cancer. In fact, second 
hand smokers are responsible for almost 600, 000 premature deaths a year which 
involved women and children with 47% and 28% respectively (World Health 
Organization, 2014).   
 
Unfortunately, there is no save level of exposure to tobacco smoke (Öberg et 
al., 2011). The force of tobacco smoke to induce cancer is due to large amount of toxic 
compounds that constitute in smoke where there are over 4,000 chemicals with at least 
40 compound can cause cancer (World Health Organization, 2014). Mainstream 
cigarette smoke contains three potent carcinogenic compounds which are polycyclic 
hydrocarbon (PAH), N-nitrosamine and aromatic amines. Different forms of these 
three major compounds can be present in smoke. For instance,  three forms of PAH 
which are benzo[a] pyrene, benzo [a] anthracene and chrysene are found in smoke 
(Rossini et al., 2008). While, eight different N-nitrosamine compounds are commonly 
present in cigarette smoke but the main ones were tobacco specific nitrosamines 
(TSNA), 4-(methylnitrosamine) -1- (3-pyridyl) - butanone (NNK) and N-
nitrosonornicotine (NNN) (Rossini et al., 2008). All the carcinogenic compounds in 
smoke cigarette required a metabolic activation to utilise their effect as such 
cytochrome P450 (CYP) enzymes, where it will react with the DNA thus inducing 
tumour. Similarly, TSNA and NNN (Humans et al., 2007) as well nicotine (Nakajima 
et al., 1996, Messina et al., 1997) were metabolized by CYP2A enzyme, an enzyme 
that expressed 90% in lung microsomes of human (Zhang et al., 2007). It causes 
damage in DNA by forming DNA adducts through covalent binding and lung cancer 
risk (Wei et al., 2000). 
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Besides, exposure to polluted environmental gases which also contain 
carcinogens other than tobacco smoke are also contributing to the development of lung 
cancer, but the burden of these exposures is small as compared to cigarette smoking 
that account for ~10% of lung cancer (Alberg & Samet, 2003). These include asbestos, 
radon, tar and soot (sources of polycyclic aromatic hydrocarbons), arsenic, chromium, 
nickel, beryllium, and cadmium (Straif et al., 2009). In fact, cigarette smoke works 
synergistically with these carcinogens thus increase the risk of lung cancer (Saracci, 
1987). Other than that, radiation exposure (Miglioretti et al., 2013) air pollution, 
(Katanoda et al., 2011), dietary factors (Marmot et al., 2007) and physical activity 
(Tardon et al., 2005) also contribute to the risk. 
 
1.6 Treatment for lung cancer 
Radiotherapy, surgery and chemotherapy are the common methods used in 
treating patients that are diagnosed with cancers. Among all these methods, 
chemotherapy is the most common practice in cancer treatment with the use of specific 
drug for specific cancers types.  Chemotherapy drugs are usually used as the first line 
in treating lung cancer. Patients with NSCLC generally have epidermal growth factor 
receptor (EGFR) mutation (Cataldo et al., 2011, Rosell et al., 2012, Wu et al., 2014). 
The EGFR mutation appears on cell surface receptor and can be classified into four 
type receptor tyrosine kinases: 1. EGFR (ERBB1 or HER1), 2. ERBB2 (Her2), 3. 
ERBB3 (Her3) and 4. ERBB4 (Her4). Binding of specific ligand or secreted growth 
factor such as epidermal growth factor (EGF) to the receptor tyrosine kinase will result 
in phosphorylation of tyrosine residues thus triggering the intracellular signalling 
cascade which are involved in induction of cell proliferation, insensitivity to apoptosis, 
activation of angiogenesis and development of metastasis  process (Salomon et al., 
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1995, Yarden & Sliwkowski, 2001). Therefore, the knowledge on EGFR mutation has 
led to focusing research on development and discovery of EGFR tyrosine kinase 
inhibitors as target-specific therapeutic agents for cancer treatment. Erlotinib (Rosell 
et al., 2012) and gefitinib that possess specific small molecule tyrosine kinase 
inhibitors has shown to be effective in inhibiting the phosphorylation in tumours 
(Cataldo et al., 2011). A part from that, in 2014 (Wu et al., 2014), an improvement of 
drug selection has been made where afatinib, an irreversible ERBB family blocker was 
introduced. It was reported that afatinib showed greater anti-cancer activity than EGFR 
tyrosine kinase inhibitor. In addition, it was reported that patients taking afatinib had 
significant longer survival as compared to patients taking the standard or 
chemotherapy regimen (platinum-based chemotherapy).  
 
At the time of diagnosis, more than half of patients with NSCLC are at advance 
stage of the disease. Generally, platinum-based is considered to be the current standard 
treatment in first line setting due to its efficiency and directly targeting DNA tumour. 
Cisplatin is one of platinum-based drugs, approved by FDA (Food and Drug 
administration) (Arnesano & Natile, 2009) in 1978 and it is the most potent anti-
tumour agents widely used in clinical regimen. In brief, the cytotoxic mode of cisplatin 
in tumour is mediated by the binding of cisplatin with DNA in the nucleus thus 
disrupting the transcription or DNA replication process, therefore, triggering the death 
of cancer cells or induction of cell apoptosis (Fuertes et al., 2003). Cisplatin is usually 
used in combination with other drugs. Several studies have reported the combination 
of cisplatin with quite a few drugs including vinorelbine and dulanermin, a 
recombinant soluble human Apo2 ligand/tumour necrosis factor-related apoptosis-
inducing ligand (TRAIL) (Ouyang et al., 2017) and oral S-1 concurrent with 
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radiotherapy (Kaira et al., 2013, Yamaguchi et al., 2013). Recently, patients with 
advanced NSCLC were treated with cisplatin in combination either of two drugs, the 
nanoparticle albumin bound (nab) paclitaxel (nab-PC) (nab-PC/cisplatin) and 
docetaxel (docetaxel/cisplatin) (Chen et al., 2017). The objective of the study was to 
compare the efficiency and safety of the drugs and it was found that nab-PC/cisplatin 
is more preferable because it causes less severe neutropenia as compared to 
docetaxel/cisplatin. In the meantime, Torigoe and colleague (Torigoe et al., 2017) 
investigated the impact of a combination of three regiments therapy which include 
drugs chemotherapy, radiation and surgery for removing tumours in advance NSCLC. 
Initially, they administered docetoxel (40 mg/m2) concurrent with cisplatin (40 mg/m2) 
through intravenous injection on day 1 and 8 and this was repeated for 3-4 week 
intervals. Radiotherapy at doses between 40-46 Gy was employed on the first day of 
chemotherapy. Finally, after a certain period, patients will undergo surgery to remove 
the tumour. The evaluation is based on the viable cells in resection tumour showing if 
the tumour contained the viable cells, therefore, an adjuvant chemotherapy will be 
given, while if no viable tumour found, the patients has completed the treatment and 
will be follow up accordingly. 
 
Although chemotherapy eradicates most of the tumorigenic cells but the 
tumour acquires resistance afterwards which is believed to be the main reason of 
cancer recurrences (Fong et al., 2010). As such, patients treated with kinase inhibitors 
frequently develop resistance within 9-12 months duration (Chen et al., 2014). 
Meanwhile, anaplastic lymphoma kinase (ALK) inhibitor, crizotinib that has 60% 
response efficiency (Shaw et al., 2014) also became ineffective after some period due 
to the resistance acquired by the tumour as it was observed that   majority of patients 
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that took the drug had cancer recurrence within 12 months (Katayama et al., 2012). 
Other than that, 53% of patients with advanced NSCLC treated with combination of 
docetoxel and cisplatin as well as exposure to radiation before resection, still able to 
develop cancer relapse (Torigoe et al., 2017).  Some tumours develop resistance after 
initial treatment such as ovarian cancer and SCLC. Whilst, NSCLC unfortunately 
develop an intrinsic resistance to cisplatin (Fuertes et al., 2003). The mechanism of 
cisplatin inducing resistance by the tumour is associated to multidrug resistance 
protein (MDR) that increase  drug efflux (Siddik, 2003, Galluzzi et al., 2012). Hence, 
reducing cisplatin accumulation may subsequently lead to lower intracellular 
concentration of drug. The remaining cells that are resistance to therapy can repopulate 
causing cancer recurrence. A great deal of research has demonstrated about the existing 
of cancer stem cells (CSCs) based on specific characteristics (Li et al., 2011, Niu et 
al., 2013) and the CSCs are well known to be associated with highly resistance 
properties and responsible for  cancer relapse.  
 
1.7 Cancer stem cells (CSCs)  
CSCs refer to a subset of tumour cells that has the ability to self-renewal and 
generate differentiated cells. These cells are referred to as CSCs to reflect their “stem 
like” properties and ability to continually sustain tumorigenesis. CSCs was first 
discovered in acute myeloid leukaemia (AML) in 1994 in which a small subset of 
leukemic cells typically similar to hematopoietic stem cells was able to develop AML 
after being transplanted into immune deficient mice (SCID) (Lapidot et al., 1994). This 
breakthrough finding has led to an intense effort made by many researchers to 
characterise and isolate CSCs from various tumour including breast (Al-Hajj et al., 
2003), brain (Singh et al., 2003, Singh et al., 2004), prostate (Collins et al., 2005), 
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pancreatic, colon (Levina et al., 2008) and lung cancer cells (Zakaria et al., 2015). 
CSCs mirror to normal stem cells in which they shared similar characteristics including 
proliferation, reproduce themselves through the process called self-renewal and 
differentiation of multilineage cells types (Visvader & Lindeman, 2008). Self-renewal 
is the ability of cells to generate more population of stem cells (self-renewal) and to 
produce differentiated cells by undergoing both symmetrical and asymmetrical 
division. In brief, symmetrical division allows the CSCs to propagate either two 
differentiated daughter cells or two stem cells. In the other way, asymmetrical division 
only resulted in one differentiated cell and one stem cells (Kawasaki et al., 2008). 
CSCs possess the capacity to develop into any cell in the overall tumour population, 
have the ability to drive a continued expansion of the population of malignant cells, 
invaded and metastasise (Yu et al., 2009).  
  
 A diverse method is being used to identify CSCs including sphere forming 
assay, Hoechst dye exclusion and detection of cell surface markers. However, the most 
widely used method for identifying CSCs is based on specific surface markers (Zhang 
et al., 2013).Various type of markers have been used and validated for CSCs. For 
instance the CD133+ is a CSCs marker for laryngeal carcinoma cells (Hep2) (Zhang 
et al., 2013) as well as AC cells (A549) (Liu et al., 2014) while the CD24+ is a positive 
marker for head and neck squamous carcinoma cells (HNSCC) (Oh et al., 2013). There 
were also several other well-accepted stem cell surface markers including the CD44, 
CD24, CD133, CD166, EpCAM which were expressed in different tumours such as 
breast, lung, pancreas, prostate, colorectal, renal, and ovarian (Jaggupilli & Elkord, 
2012). An example is the epithelial cell adhesion molecule known as the EpCAM, 
mostly expressed in several human carcinoma and in the majority of normal epithelial 
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cells (Laimer et al., 2008). Due to the strong association between high EpCAM 
expression and the progression of tumour cells in NSCLC, it is believed that this 
molecule would serve as a prominent marker that can distinguish CSCs from the non-
CSCs in tumour specimen which are mostly consisted of squamous cell carcinoma 
(Litvinov et al., 1996, Munz et al., 2009, Pak et al., 2012). In addition, EpCAM was 
noticed to be an important biomarkers due to the ability to detect circulating tumour 
cells in blood of lung cancer patients (Skirecki et al., 2014). Another example is the 
leukocyte cell adhesion molecule (ALCAM) or CD166 that is also found to be a robust 
marker in lung CSC, based on the high expression detected in most lung cancer 
samples and the capacity of the isolated cells to exhibit self-renewal capacity and 
differentiation in vivo (Zhang et al., 2012a, Tachezy et al., 2014). 
 
1.8 Targeting CSCs  
The existence of CSCs plays a major role in chemotherapeutic resistance and 
cancer recurrence. Although CSCs have a minority population in the tumour subset, 
but they are known to be the driving force behind tumour growth besides preserving 
their stemness. A more strategic method is needed to discriminate CSCs population 
from other cell population. As mentioned earlier, CSCs are a unique population that 
have similarities to normal stem cells which relatively capable to initiate tumour 
growth, actively proliferating cells, possess self-renewal characteristics, have 
resistance to chemotherapeutic drugs and able to metastasise, thereby making them 
responsible for tumour recurrence or relapse. CSCs can be targeted through their 
cellular properties such as inhibiting the self-renewal capability, suppressing their 
migration, blocking the chemo-resistance and interrupting the CSCs niche. Hence, 
targeting CSCs may be a promising strategy for improved cancer treatment. 
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1.8.1 Self-renewal of CSCs 
Many studies have discovered the role of SOX2 in the regulation of self-
renewal ability of CSCs of many tumours. A recent study (Lee et al., 2014) in HNSCC 
has proved that the overexpression of SOX2 in tumour cells has exhibited a formation 
of sphere which is a definite hallmark of self-renewal properties. Furthermore, their 
study also showed that the overexpression of SOX2 was associated with the enrichment 
of CD44 positive, a stemness marker used in HNSCC. Also, another study using side 
population (SP) derived from lung cancer (D121) which contain CSCs characteristic 
also demonstrated the up regulation of SOX2 (Xiang et al., 2011). Therefore, SOX2, a 
transcription factor of CSCs, has been targeted in order to inhibit the CSCs as such 
using rapamycin, a mammalian mTOR (mammalian target of rapamycin)  inhibitor 
since mTOR has been suggested to play a critical role specifically in stemness of CSCs 
(Xie et al., 2016). They found A549 spheres that highly expresses OCT-4, TWIST, 
NANOG, SOX2, CD133, ABCG1, ABCG2 and ABCG4 was significantly inhibited after 
treatment with rapamycin. In conjunction to this, the expression of SOX2 was 
significantly reduced upon the treatment suggesting SOX2 plays a crucial role in 
controlling the CSCs functions. Apart from self-renewal properties, SOX2 also was 
correlated with other stemness features including cells proliferation, invasiveness, 
chemo-resistance and induction of tumour (Xiang et al., 2011, Zhu et al., 2012, Liu et 
al., 2013, Lee et al., 2014, Xie et al., 2016). 
 
Besides SOX2, the NANOG also regulates the self-renewal in CSCs. In a study, 
the NANOG Positive CSCs were isolated from human hepatocellular carcinoma (HCC) 
and it was found that these isolated cells have enhanced ability of self-renewal and 
clonogenicity which are consistent with crucial CSCs hall mark. They proved NANOG 
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Positive cells could form spheres efficiently as well as capable to induce more and larger 
colonies with more than 60% of colonies are identify as holoclones type comparing to 
NANOG Negative Cells (Shan et al., 2012). The NANOG Positive cells also demonstrate 
that they are more resistant to sorafenib and cisplatin drug as they are less sensitive to 
the therapy since NANOG Positive cells are known to overexpress multidrug resistance 
protein1 (MDR1), lung resistance protein (LRP) and multidrug resistance associate 
protein (MRP) as compare to NANOG Negative Cells. In addition, the NANOG Positive 
cells also display more migratory and invasive activities as evidence of decreasing 
expression of E-cadherin and increasing expression of vimentin and fibronectin, a 
molecular marker for epithelial mesenchymal transition (EMT).  
 
OCT-4, also known as a member of the family of POU-domain transcription 
factors are known as key regulators in CSCs. Lung cancer derived CD133+ (LC-
CD133+) was suggested  to associate with self-renewal (Ponti et al., 2005) and 
stemness properties due to up-regulation of OCT-4 expression. Yu-Chih and 
colleagues (Chen et al., 2008) showed that the knockdown of OCT-4 in LC-CD133+ 
subsequently altered the morphology of the cells from floating spheres to epithelial-
like cells. Perhaps, the effect of OCT-4 knockdown continuously improves the chemo 
radiotherapeutic sensitivity in CD133+ thus effectively inducing the apoptotic activity 
as annexin V and caspase 3 were expressed. SOX2, NANOG, OCT3/4, Nestin and 
CD34 which are common specific molecular targets in CSCs have been extensively 
studied as each of these genes plays important role in the functioning of CSCs. Isolated 
CSCs from breast cancer patient with stage I, II, III and IV demonstrated that the 
expression of stemness transcription factor increased according to the stage of the 
diseases. Based on their data, they showed some of these transcription factors are 
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related to maintenance of the stemness while others might responsible for diseases 
progression (Apostolou et al., 2012). Similarly, Kruppel-like factor (KLF4) is also one 
of the factors contributing to self-renewal in CSCs. In fact, KLF4 is one of the four 
transcription factors used in creating induced pluoripotent stem cells (iPSCs). In breast 
CSCs, consistent overexpression of KLF4 led to the enrichment of CSCs while 
knockdown of KLF4 has resulted in decreasing the mammosphere, colonies formation 
as well as inhibited the tumorigenesis in immunocompromised NOD/SCID mice (Yu 
et al., 2011). In addition, all these four transcription factors, SOX2 (Lee et al., 2014, 
Xiang et al., 2011, Liu et al., 2013b), NANOG (Shan et al., 2012), POU51F (Chen et 
al., 2008) and KLF4 (Yu et al., 2011, Yan et al., 2016) showed similar roles where 
they also responsible for migration of CSCs which is involved in the metastasis process 
in CSCs. 
 
1.8.2 Metastasis of CSCs 
Cancer begins as localise disease that if left untreated it will metastasise to 
other parts of organ in the body and be referred to as malignant tumour. It was proposed 
that CSCs is responsible in initiating the metastasis process and research regarding 
CSCs associated with metastasis has been extensively studied. The metastasis of 
cancer cells may result from the resistant of CSCs to conventional chemotherapy and 
this inherit resistant eventually leads to relapse in many cancer patients (Dean et al., 
2005). Metastasise cells require several steps before migrating to other parts of organ 
tissue. The process involved EMT. The tumours cells must invade through the tissue 
and entering the blood circulation before establishing a new tumour. CSCs are believed 
to be the cells that metastasise (Berx et al., 2007) since it’s the only cells that capable 
to initiate tumours. In fact, Bhagwandin et al. has demonstrated the SP isolated from 
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pancreatic carcinoma (Panc-1) which is enriched with CSCs showed aggressive 
metastatic effect and had produced primary tumours. This primary tumour from SP 
population also expresses ABCG2, an important source of drug resistance. Besides, 
another study showed the drug surviving cells (DSC) that own the properties of CSCs 
exhibit high metastatic capacity. Following inoculation of tumour cells in SCID mice, 
the DSCs had form numerous tumours in the lung  with increase expression of 
adhesion molecules (VLA-5,ICAM-1 and VCAM-1) as well as MMP2 and MMP3 
indicating the metastatic potential of CSCs (Levina et al., 2008). This is because 
metastasis is a selective process which requires tumour cells to survive during 
extravasation and invasion process through a distant part of the body. Therefore, only 
CSCs have the ability to survive during this process.  
 
1.8.3 Chemo-resistance in CSCs 
Chemotherapy is designed to target rapidly dividing cells through interrupting 
the DNA replication process thus inducing cell apoptosis. One of the primary reasons 
for chemotherapy failure is due to drug resistance. Chemotherapy generally destroys 
drug sensitive cells but not the drug resistant cells. It is suggested that drug resistant 
cells are employed by CSCs population for progression and replication and this is the 
most challenging for cancer chemotherapy. In normal stem cells, to maintain the tissue 
and biological function of life, stem cells are protected from carcinogenic endogenous 
or exogenous agents in order to avoid any damage that disturb the function of the cells 
(Dekaney et al., 2009). Likewise, CSCs also possess similar features to protect them 
against chemotherapy drugs such as overexpression of MDR pumps. MDR pumps are 
a protective system that pumps out any chemicals or biotoxic against the CSCs. Also. 
ABC transporter family, including ABCA2, MDR1, and MRP1 are potential drug 
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pumps which are known to associate with drug resistance (Fong et al., 2010, Ho et al., 
2007). Besides the aldehyde dehydrogenase (ALDH) family is also responsible for 
CSCs resistance to conventional chemotherapeutic drugs. ALDH could oxidize the 
aldehyde group of chemotherapy drugs to carboxylic acid, in that way detoxifying the 
cytotoxic chemotherapy drugs and metabolising them resulting into non-toxic forms. 
ALDH as well  plays a vital role in ROS scavenging activity which protects tumour 
from oxidative stress injury that normally induced by radiation and chemotherapeutics 
(Xu et al., 2015). Chemo-resistant of CSCs may be explained by their state of 
quiescence or dormancy in order to preserve the self-renewal in stem like cell. The 
dormant CSCs are usually in undividing mode thus making them exhibit slow 
proliferation kinetics. Meanwhile, chemotherapeutic drugs are designated to attack the 
rapidly dividing cells, therefore making the dormant CSCs escape and survive from 
chemo drugs. Furthermore, the dormant CSCs are able to remain quiescence for years 
thus making CSCs an ideal candidate to explain the tumour recurrence (Maugeri-Saccà 
et al., 2011). Dormant CSCs is regulated by intrinsic and extrinsic signals from 
microenvironment interaction (Wilson & Trumpp, 2006). These interaction is critical 
for maintenance of CSCs dormancy (Spradling et al., 2001). 
 
1.8.4 CSCs niche 
Stem cells usually reside in a particular environment called the “stem cell 
niche” to maintain the stem cells and  act as a homing for stem cells residues 
(Januschke & Näthke, 2014). The niche regulates the stemness, proliferation, 
metastasis and resistance of stem cells. The behaviour of stem cells is tightly controlled 
by the signals from the surrounding niche which eventually determined the cells fate 
(Kasai et al., 2014). Analogously, CSCs was surrounded by “cancerous niche” helping 
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them to retain their self-renew ability and propagate more differentiated progenitor 
cells while staying in undifferentiated state (Calabrese et al., 2007, Hill et al., 2009). 
The niche is enriched with nutrients, extracellular matrix, soluble factor, vascular 
network and metabolic process. The stroma cells that reside as a cellular part in niche 
recruit many others cell types including the immunological cells upon receiving 
signals from tumour cells, therefore, forming an additional inflammatory 
microenvironment (Fazilaty et al., 2013). The tumour microenvironment is a product 
of cell-cell interactions and cell-ECM (extracellular matrix) interactions. Tumours 
cells secreted a variety of proteins capable of providing signal that turn on the 
transcription factor thus regulating the CSCs activities. Proteins secreted by tumour 
cells in ECM microenvironment are commonly involved in cell adhesion, motility, 
intercellular communication and invasion. The niche contributes to pre-metastasis, an 
initial event of metastasis (Kaplan et al., 2005). For tumour cells to progress and 
develop themselves, they must have the ability to  migrate, the capacity to degrade 
tissue matrix (ECM), capable to survive in blood and able to establish itself in new 
tissue environment (Mbeunkui & Johann, 2009). Numerous secreted proteins 
identified in tumour niche could be molecular therapeutic targets such as hypoxia-
inducible factor 1, MMP-2, MMP-9 and MMP-12, nuclear factor of κB (NF κB), 
tumour necrosis factor (TNF), interleukin (IL-6) , vascular endothelial growth factor 
(VEGF), Integrin αvβ3 and αvβ5 (Mbeunkui & Johann, 2009).  
 
The CSCs niche has been implicated with resistance and metastasis of CSCs 
as they survive conventional treatment. Perhaps, CSCs niche also play a protective role 
by sheltering the cells from diverse genotoxic agents that could harm the cells thus 
contributing to therapy resistance (Folkins et al., 2007, Hovinga et al., 2010). Hence, 
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targeting the CSCs niche may be a promising strategy for elimination of CSCs 
population. The niche of CSCs is mediated by hypoxia condition which often 
insufficient of oxygen supply (Lin & Yun, 2010). A study on breast cancer showed 
that carbonic anhydrase IX (CIAX), a metalloenzyme was up regulated in hypoxic 
tumours. CIAX regulated internal pH contributing to the acidification of the niche 
thereby enhancing cancer cells proliferation, invasion and metastasis by promoting 
EMT process (Lock et al., 2013). Therefore, inhibiting the CIAX in CSCs niche by 
specific small molecule inhibitor results in depletion of CSCs which in turns, leads to 
tumour growth and metastasis reduction. Similarly, a hypoxia condition was induced 
by high concentration of gefitinib under normoxic (hypoxic conditions) causing 
gefitinib-resistant persisters (GRPs) in NSCLC and is associated with high expression 
of CD133, OCT4, SOX2, NANOG, CXCR4, and ALDH1A1 as well exhibiting 
tumorigenicity in vivo. Furthermore, the hypoxia condition in GRP significantly 
increased and activated insulin like growth factor 1 (IGF1) thereby enhancing 
resistance in chemotherapy. Consequently, inhibiting the IGF1 may assist in sensitivity 
of CSCs to chemotherapy drugs (Murakami et al., 2014). Apart from that, the CSCs 
niche is also responsible for regulating the conversion of CSCs from non-CSCs. 
Shiozawa et el. (Shiozawa et al., 2016) demonstrated that co-culture of prostate cancer 
and osteoblasts niche which is influenced by growth arrest specific 6 (GAS6) cause a 
significance shift of non-CSCs to CSCs. Thus, targeting only CSCs will limit the 
therapeutic efficiency because the CSCs niche also play a vital role in maintaining the 
CSCs by repopulating the non-CSCs to CSCs. 
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1.9 Curcumin as anti-cancer 
Recent research has suggested that plant-based foods have health promoting 
effects (Meng et al., 2017) and prevention properties (Aggarwal & Shishodia, 2006). 
There are many phytochemicals that have been revealed to regulate multiple oncogenic 
targets involved in cancer growth, proliferation, chemo resistance, invasion, and 
metastasis. Moreover, certain phytochemicals have been identified as targets for CSC 
stemness (Singh et al., 2017). Phytochemical has been suggested to overcome cancer 
drug resistance (Fong et al., 2010). A number of phytochemicals, a naturally occurring 
substance, have been demonstrated to possess anti-tumour effects in various 
experimental systems. The use of phytochemicals derived from dietary components 
has attracted many public and scientific interests in order to combat human diseases, 
especially the cardiovascular disease and cancer, the two most common killers in 
developed countries. (Sharma et al., 2005). This is because they afford the opportunity 
to affect many different targets or portions of the signal transduction pathway that 
modulate gene expression, cell cycle progression, cell mortality, metabolism and 
apoptosis (HemaIswarya & Doble, 2006). Among natural products used in medicine, 
polyphenols have been found to possess chemo-preventive, chemo-protective, chemo-
sensitising, radio-sensitising and  radio-protective activities (Jagetia et al., 2008).   
 
Curcumin is a well-known dietary polyphenol derived from the rhizomes of 
turmeric (curcuma longa), which is also a member of ginger family (Zingiberaceae) 
and Indian spice, usually used in preparation of mustard and curry (Sharma et al., 
2005). The bright yellow of turmeric came from fat-soluble, polyphenolic pigments 
known as curcuminoids. Curcuminoids can be sub classified into three groups 
including diferuloylmethane which is also refer as curcumin, desmethoxycurcumin 
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and bis-desmethoxycurcumin (Akram et al., 2010). Commercially, curcuminoids 
contains approximately 77% diferuloylmethane, 17% desmethoxycurcumin, and 6% 
bisdemethoxycurcumin (Anand et al., 2007). Curcumin is the most active compound 
and can exist in at least two tautomeric forms, namely as keto and enol. The enol form 
is more energetically stable in the solid phase and in solution (Akram et al., 2010). 
Therefore, chemically, curcumin is a bis-R, -unsaturated -diketone (commonly called 
diferuloylmethane) as depicted in Figure 1.1, which exhibits keto–enol tautomerism 
having a predominant keto form in acidic and neutral solutions and stable enol form in 
alkaline medium. In pure turmeric powder, curcumin, the active compound contained 
3.14% of concentration by weight (Tayyem et al., 2006). Traditionally, curcumin has 
been used as part of ancient Indians medical system known as Ayuverda to treat eye 
infections, to dress wounds, treat bites, burn, acne and many various skin diseases 
(Thakur et al., 1989). In Northern India, women after childbirth were given a hot glass 
of milk containing the mixture of turmeric paste with powder of dried ginger roots and 
honey to drink twice daily (Pandeya, 2005). 
 
 
 
 
 
 
Figure 1. 1 Structure of curcumin 
 
1.10 Pleiotropic role of curcumin 
Curcumin is well known to possess the pleiotropic role such as anti-
inflammatory, anti-oxidant, anti-microbial and anti-cancer which  has been intensively 
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studied as a cancer model in breast, ovarian, prostate, colon, pancreatic, melanoma and 
head and neck cancers, over the decade (Li & Zhang, 2014).  Exciting recent studies 
have shown that curcumin, either alone or in combination with other anti-cancer 
agents, has a pleiotropic therapeutic effect in cancer (Notarbartolo et al., 2005). 
Additionally, curcumin is also known to down-regulate the intracellular levels of three 
major ABC drug transporters; p-glycoprotein (P-gp), MRP-1 and ABCG2 that are 
important MDR (Ebert et al., 2007, Febbo & Ilio, 2008, Hou et al., 2008, Andjelkovic 
et al., 2008). Previous research demonstrated that curcumin in combination with 
doxorubicin could result in better treatment of human hepatic cancer cells 
(Notarbartolo et al., 2005). Amiji and Ganta (2009) have also demonstrated that 
simultaneous administration of curcumin and paclitaxel able to overcome drug 
resistances. Yu et al (2009) has reported that curcumin with no discernible toxicity 
synergises with 5-FU plus oxaliplatin (FOLFOX) to inhibit the growth of colon cancer 
cells (Yu et al., 2009). Their study also reveal that curcumin either alone or together 
with FOLFOX could be effective in eliminating CSCs (Yu et al., 2009). Another study 
by Zhang et al., (2013) indicated that curcumin has the ability to induce the sensitivity 
of CD133+ CSCs to cisplatin and therefore enhance the effectiveness of cisplatin on 
the Hep-2 cell line as manifested by the reduction expression of ABCG2 in CD133+ 
cells which suggested that it is responsible for the induction of sensitivity of CD133+ 
cells to cisplatin (Zhang et al., 2013). In addition, curcumin has been found to be safe, 
with no dose-limiting toxicity, when administered at doses up to 10 g/day in humans 
(Yum et al., 2001).  
 
Apart from that, curcumin also has high anti-metastatic effect. Metastasis 
involve the process of spreading the cancer cells by migration ability from primary site 
